{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:10:20Z","timestamp":1758478220011},"reference-count":74,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.tcm.2017.12.011","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T18:21:33Z","timestamp":1514485293000},"page":"348-354","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["LDL cholesterol: How low to go?"],"prefix":"10.1016","volume":"28","author":[{"given":"Chris J.","family":"Packard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2017.12.011_bib0001","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0140-6736(17)32292-4","article-title":"Very low LDL-cholesterol concentrations achieved: which target is next?","volume":"390","author":"Hovingh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0002","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamacardio.2017.2293","article-title":"Low-density lipoprotein cholesterol treatment in the proprotein convertase subtilisin\/kexin type 9 inhibitor era: getting back on target","volume":"2","author":"Sabatine","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.tcm.2017.12.011_bib0003","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.12.011_bib0004","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"23","author":"Piepoli","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jama.2017.6765","article-title":"Inconsistent guideline recommendations for cardiovascular prevention and the debate about zeroing in on and zeroing LDL-C levels with PCSK9 inhibitors","volume":"318","author":"Ioannidis","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0006","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/jama.2017.6753","article-title":"Treatment of cholesterol in 2017","volume":"318","author":"Krumholz","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0007","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease","volume":"314","author":"Pandya","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0008","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial (letter)","volume":"318","author":"Kazi","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0009","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0010","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1001\/jama.2016.15085","article-title":"Statins for primary prevention: the debate is intense but the data are weak","volume":"316","author":"Redberg","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0011","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0012","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MOL.0000000000000456","article-title":"New approaches to address dyslipidemia","volume":"28","author":"Parhofer","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0014","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.12.011_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(17)30752-3","article-title":"Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study","volume":"389","author":"Kaplan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0016","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-finction mutations in PCSK9 and identification of a compound heterozygore","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0018","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0002-9149(99)00095-8","article-title":"Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia","volume":"83","author":"Raal","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0019","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.12.011_bib0020","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.1983.03340140039025","article-title":"Lipid Research Clinics Program reference values for hyperlipidemia and hypolipemia","volume":"250","author":"Rifkind","year":"1983","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2796.1997.00238.x","article-title":"The influence of age on low density lipoprotein metabolism: effects of cholestyramine treatment in young and old healthy male subjects","volume":"242","author":"Ericsson","year":"1997","journal-title":"J Intern Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0022","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0023","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0024","first-page":"1883","article-title":"Randomised trial of cholesterol lowering in 4444patients with coronary heart disease: the Scandinavian Simvastatin Survival Study","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0026","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0027","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0028","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0029","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.2015.10017","article-title":"New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines","volume":"314","author":"Shrank","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11886-017-0940-0","article-title":"HDL cholesterol metabolism and the risk of CHD: new insights from human genetics","volume":"19","author":"Vitali","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.tcm.2017.12.011_bib0031","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"ACCELERATE Investigators. evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0032","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a pre-specified analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0033","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMe1507041","article-title":"Proof that lower is better: LDL cholesterol and IMPROVE-IT","volume":"372","author":"Jarcho","year":"2015","journal-title":"N. Eng. J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0034","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0035","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0036","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0037","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0038","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0039","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nrcardio.2012.15","article-title":"Pharmacotherapy: statins and new-onset diabetes\u2014the important questions","volume":"9","author":"Preiss","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0040","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a pre-specified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tcm.2017.12.011_bib0041","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0042","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.tcm.2017.12.011_bib0043","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0044","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1194\/jlr.R004119","article-title":"Lipids and the ocular lens","volume":"51","author":"Borchman","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.tcm.2017.12.011_bib0045","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.tcm.2017.12.011_bib0046","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.12.011_bib0047","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.atherosclerosis.2016.09.059","article-title":"Coronary atheroma progression rates in men and women following high-intensity statin therapy: a pooled analysis of REVERSAL, ASTEROID and SATURN","volume":"254","author":"Stegman","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2017.12.011_bib0048","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0049","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease. HPS3\/TIMI55-REVEAL Collaborative Group","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.12.011_bib0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1194\/jlr.M032615","article-title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib","volume":"54","author":"Davidson","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.tcm.2017.12.011_bib0051","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jama.2017.11750","article-title":"Genetic studies help clarify the complexities of lipid biology and treatment","volume":"318","author":"Sniderman","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0052","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0053","series-title":"Endotext [Internet].","article-title":"Rare genetic disorders altering lipoproteins","author":"Shapiro","year":"2000-2015"},{"key":"10.1016\/j.tcm.2017.12.011_bib0054","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCULATIONAHA.116.025897","article-title":"Unpacking and understanding the impact of proprotein convertase subtilisin\/kexin type 9 inhibitors on apolipoprotein B metabolism","volume":"135","author":"Packard","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.12.011_bib0056","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/MOL.0000000000000230","article-title":"Long term follow up of lipid lowering trials","volume":"26","author":"Packard","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0057","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jacl.2017.05.005","article-title":"Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg\/dL compared with a novel low-density lipoprotein estimation method","volume":"11","author":"Whelton","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"92","key":"10.1016\/j.tcm.2017.12.011_bib0058","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"15","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0059","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":".Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0060","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Europ","volume":"23","author":"Kotseva","year":"2016","journal-title":"J Prev Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0061","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.12.011_bib0062","doi-asserted-by":"crossref","first-page":"e003201","DOI":"10.1161\/CIRCOUTCOMES.116.003201","article-title":"Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome","volume":"10","author":"Pokharel","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.tcm.2017.12.011_bib0063","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw572","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic","author":"Sabatine","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.12.011_bib0064","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial (letter)","volume":"318","author":"Kazi","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0065","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0066","article-title":"Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia","year":"2016","journal-title":"Technology appraisal guidance [TA393]"},{"key":"10.1016\/j.tcm.2017.12.011_bib0067","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0068","article-title":"2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.12.011_bib0069","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2017.12.011_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.tcm.2017.12.011_bib0071","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2017.12.011_bib0072","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"Test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0073","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","article-title":"Remnant lipoproteins","volume":"28","author":"Varbo","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.tcm.2017.12.011_bib0074","article-title":"\u2018Highest risk-highest benefit\u2019 strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies","author":"Annemans","year":"2017","journal-title":"Eur Heart J"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173817302037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173817302037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T15:42:35Z","timestamp":1534261355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173817302037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1050173817302037"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2017.12.011","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL cholesterol: How low to go?","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2017.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}